Diagnosis and management of stage a heart failure.

Congest Heart Fail

Department of Medicine, University of Wisconsin, Madison, WI 53792-3220, USA.

Published: July 2006

Reduction of the monetary and societal costs of the heart failure epidemic can best be achieved by prevention of new heart failure cases. To effectively prevent heart failure, patients at risk must be identified and treated. The American College of Cardiology/American Heart Association Guidelines for Evaluation and Management of Chronic Heart Failure in the Adult define the stage A heart failure patient as one with identified risk factors for heart failure, particularly coronary heart disease, hypertension, and diabetes, but no evidence of cardiovascular damage. In this review, the authors discuss the commonly recognized, as well as some less commonly recognized, risk factors that define the stage A patient. The authors also discuss data demonstrating that risk factor modification can reduce heart failure incidence. Given the size of the population at risk, through increased awareness of heart failure risk and aggressive treatment, health care providers can critically impact this public health concern.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1527-5299.2006.04621.xDOI Listing

Publication Analysis

Top Keywords

heart failure
36
heart
11
failure
9
stage heart
8
define stage
8
risk factors
8
authors discuss
8
commonly recognized
8
risk
6
diagnosis management
4

Similar Publications

The burdens of cardiovascular (CV) diseases and cardiotoxic side effects of cancer treatment in oncology patients are increasing in parallel. The European Society of Cardiology (ESC) 2022 Cardio-Oncology guidelines recommend the use of standardized risk stratification tools to determine the risk of cardiotoxicity associated with different anticancer treatment modalities and the severity of their complications. The use of the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) is essential for assessing risk prior to starting cancer treatment, and validation of these methods has been performed in patients receiving anthracyclines, human epidermal receptor 2 (HER2)-targeted therapies and breakpoint cluster region-abelson oncogene locus (BCR-ABL) inhibitors.

View Article and Find Full Text PDF

High cardiac sympathetic drive and release of the sympathetic cotransmitter neuropeptide Y (NPY) are significant features of congestive heart failure (CHF), in which resting venous NPY levels are known to be associated with mortality. However, whether circulating NPY levels increase during exercise in CHF when they are already elevated is controversial. We sought to establish the dynamics of circulating NPY levels in CHF patients treated with contemporary medical therapy and devices in relationship to indices of performance linked to long-term prognosis.

View Article and Find Full Text PDF

Sarcopenia, an age-related decline in skeletal muscle mass, strength, and function, is increasingly recognized as a significant condition in the aging population, particularly among those with cardiovascular diseases (CVD). This review provides a comprehensive synthesis of the interplay between sarcopenia and cardiogeriatrics, emphasizing shared mechanisms such as chronic low-grade inflammation (inflammaging), hormonal dysregulation, oxidative stress, and physical inactivity. Despite advancements in diagnostic frameworks, such as the EWGSOP2 and AWGS definitions, variability in criteria and assessment methods continues to challenge standardization.

View Article and Find Full Text PDF

Background/objectives: Chronic gut dysbiosis due to a high-fat diet (HFD) instigates cardiac remodeling and heart failure with preserved ejection fraction (HFpEF), in particular, kidney/volume-dependent HFpEF. Studies report that although mitochondrial ATP citrate lyase (ACLY) supports cardiac function, it decreases more in human HFpEF than HFrEF. Interestingly, ACLY synthesizes lipids and creates hyperlipidemia.

View Article and Find Full Text PDF

Diabetes mellitus (DM) is a multifaceted disorder with a pandemic spread and a remarkable burden of cardiovascular mortality and morbidity. Diabetic cardiomyopathy (DBCM) has been increasingly recognized as the development of cardiac dysfunction, which is accompanied by heart failure (HF) symptoms in the absence of obvious reasons like ischemic heart disease, hypertension, or valvulopathies. Several pathophysiological mechanisms have been proposed, including metabolic disorders (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!